Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corp (NASDAQ:UTHR), a pharmaceutical company with impressive 89% gross profit margins and a perfect Piotroski Score of 9 according to InvestingPro, recently sold shares of the company’s stock totaling approximately $3.08 million. The transactions, which took place on June 12, saw Mahon sell a series of shares at prices ranging from $275.98 to $282.27 per share.
In addition to these sales, Mahon exercised stock options to acquire 11,000 shares at a price of $135.42 per share, amounting to a total of $1,489,619. Following these transactions, Mahon holds 36,781 shares of United Therapeutics common stock. The sales were executed under a pre-arranged 10b5-1 trading plan, which was established on December 24, 2024.
In other recent news, Insmed (NASDAQ:INSM) Incorporated announced positive results from its Phase 2b study of Treprostinil Palmitil Inhalation Powder (TPIP) for pulmonary arterial hypertension. The study met all primary and secondary efficacy endpoints, demonstrating a significant reduction in pulmonary vascular resistance and improvements in patient outcomes. Insmed plans to engage with the FDA for Phase 3 trial designs, with studies expected to begin before the end of 2025. Meanwhile, Liquidia Technologies (NASDAQ:LQDA) received a favorable court ruling, allowing the commercialization of its lung-disease drug Yutrepia, following the dismissal of United Therapeutics’ legal claims. This legal win has paved the way for Liquidia to launch Yutrepia, competing with United Therapeutics’ Tyvaso. Raymond (NSE:RYMD) James analysts maintained a Strong Buy rating on Liquidia, reflecting optimism for the company’s future product launches. United Therapeutics, on the other hand, received reaffirmed Outperform and Buy ratings from Leerink Partners and TD Cowen, respectively. Analysts expressed optimism about United Therapeutics’ Tyvaso and its potential expansion into treating idiopathic pulmonary fibrosis, as well as the company’s innovative xenotransplantation platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.